Clinical and pathological spectrum of disease severity among patients with acute liver failure (ALF) undergoing deceased donor liver transplantation
Listing and transplanting patients with acute liver failure (ALF) is challenging, requiring rapid assessment of the likelihood of recovery. The availability of a large number of ALF liver explants, along with their clinical data, afforded an opportunity to retrospectively evaluate liver transplantation (LT) decision-making. We hypothesized that, with the benefit of hindsight, a small number of patients might have recovered without LT. Three hundred liver explants from ALF patients of varying etiologies who had undergone LT over 22 years in the Acute Liver Failure Study Group registry were reviewed for histopathological features and degree of necrosis by a committee of 8 hepatopathologists. A second committee of 8 experienced transplant hepatologists independently reviewed clinical data on these same 300 patients and retrospectively scored the likelihood that each patient required transplantation. Only 3 (1%) of those reviewed by the Clinical Committee were considered to "Definitely" not require liver grafting, while an additional 10 (3.3%) were deemed to "Possibly" not require transplantation (Not Likely Group, N=13). There was no difference in the degree of necrosis in explants in these groups, when compared to the remaining Likely Group, N=287 (95.6%), except in acetaminophen (APAP)-associated ALF, where the degree of necrosis was more uniformly graded as severe, correlating with the need for transplantation. Virtually every patient undergoing LT for ALF retrospectively appeared to need their transplant, based on expert clinical consensus review. Overall, there was poor correlation between clinical severity and apparent degree of necrosis seen in the 300 liver explants, except perhaps for APAP subjects.
Authors
- Guang‐Yu Yang (ORCID: https://orcid.org/0000-0002-5987-7750)
- Shannan R. Tujios (ORCID: https://orcid.org/0009-0005-8273-9400)
- David E. Kleiner (ORCID: https://orcid.org/0000-0003-3442-4453)
- Jorge L. Rakela (ORCID: https://orcid.org/0000-0002-7088-9779)
- Adrian Reuben
- Ryan M. Gill (ORCID: https://orcid.org/0000-0001-6229-7928)
- Norman Sussman (ORCID: https://orcid.org/0000-0001-8190-2396)
- R. Todd Stravitz
- Robert J. Fontana (ORCID: https://orcid.org/0000-0001-9161-5892)
- William M. Lee (ORCID: https://orcid.org/0000-0002-2783-5441)
- Jody A. Rule (ORCID: https://orcid.org/0000-0002-4019-372X)
- Bryce Hatfield (ORCID: https://orcid.org/0000-0001-7850-9745)
- Hanlin Wang (ORCID: https://orcid.org/0000-0001-9659-1738)
- Daniel Ganger (ORCID: https://orcid.org/0000-0003-1114-4192)
- Eun-Young Choi (ORCID: https://orcid.org/0000-0002-7319-8826)
- Matthew M. Yeh
- Nathan M. Bass
- Lan Peng
Institutions
- Northwestern University (US)
- Medical University of South Carolina (US)
- Schlumberger (British Virgin Islands) (VG)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Baylor College of Medicine (US)
- Virginia Commonwealth University (US)
- University of Washington (US)
- University of Michigan (US)
- WinnMed (US)
- Southwestern Medical Center (US)
- Durect (United States) (US)
- National Cancer Institute (US)
- Mayo Clinic in Florida (US)
- Northwestern Medicine (US)
- Southwestern Medical Center (US)
- University of San Francisco (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Liver Transplantation
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1097/lvt.0000000000000634
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 0.00